Literature DB >> 16741917

The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.

Marcio C Bajgelman1, Bryan E Strauss.   

Abstract

BACKGROUND: Some nuances of mutant and wild-type p53 activity have been uncovered utilizing temperature sensitive (TS) alleles. However, few human tumor derived cell lines possess a TS p53 mutant.
METHODS: The cell lines DU145 (heterozygous p53, P223L, and V274F) and PC3 (p53-null, where exogenous P223L and V274F were introduced individually or in combination) were examined for TS p53 activity as revealed by reporter construct and target gene activation.
RESULTS: TS p53 function was observed in DU145 and expression of the P223L allele in PC3 conferred a TS p53 profile. Activation of p21Waf1 demonstrated that P223L TS activity may have been influenced by cellular context.
CONCLUSIONS: The DU145 cell line harbors a TS mutant of p53 and, in addition to being a widely used model of human prostate carcinoma, may also reveal new insights into p53 function due to the unique transcriptional properties of its TS phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741917     DOI: 10.1002/pros.20462

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.

Authors:  Rajan Gogna; Esha Madan; Periannan Kuppusamy; Uttam Pati
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

2.  Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect.

Authors:  Bradley T Scroggins; Masayuki Matsuo; Ayla O White; Keita Saito; Jeeva P Munasinghe; Carole Sourbier; Kazutoshi Yamamoto; Vivian Diaz; Yoichi Takakusagi; Kazuhiro Ichikawa; James B Mitchell; Murali C Krishna; Deborah E Citrin
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

3.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

4.  Proteasome inhibitors suppress the protein expression of mutant p53.

Authors:  Marianna Halasi; Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

6.  AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment.

Authors:  Wei He; Min-Guang Zhang; Xiao-Jing Wang; Shan Zhong; Yuan Shao; Yu Zhu; Zhou-Jun Shen
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

Review 7.  Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Authors:  Bernard Leroy; Luc Girard; Antoinette Hollestelle; John D Minna; Adi F Gazdar; Thierry Soussi
Journal:  Hum Mutat       Date:  2014-05-06       Impact factor: 4.878

8.  Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector.

Authors:  Paula Fratini; Bryan E Strauss
Journal:  Virol J       Date:  2010-01-22       Impact factor: 4.099

9.  Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo.

Authors:  Kun-Huang Yan; Yung-Wei Lin; Chi-Hao Hsiao; Yu-Ching Wen; Ke-Hsun Lin; Chung-Chi Liu; Mao-Chih Hsieh; Chih-Jung Yao; Ming-DE Yan; Gi-Ming Lai; Shuang-En Chuang; Liang-Ming Lee
Journal:  Oncol Lett       Date:  2013-03-15       Impact factor: 2.967

10.  Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling.

Authors:  Kun-Huang Yan; Chih-Jung Yao; Chi-Hao Hsiao; Ke-Hsun Lin; Yung-Wei Lin; Yu-Ching Wen; Chung-Chi Liu; Ming-DE Yan; Shuang-En Chuang; Gi-Ming Lai; Liang-Ming Lee
Journal:  Oncol Lett       Date:  2013-02-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.